The Roche-sponsored symposium at Alzheimer Europe explored how disease-modifying therapies can deliver meaningful benefits for people with Alzheimer’s disease and their families. Dr Claire Lansdall (Roche) discussed the importance of drug development informed by people living with Alzheimer’s disease and their care partners.
Professor Xavier Montalban (ACE, Barcelona) shared insights from multiple sclerosis, comparing biological markers like PET scans and MRI lesions, while addressing Health Technology Assessment (HTA) and reimbursement hurdles across Europe.
Chris Lynch (Alzheimer's Disease International) emphasised updating national dementia strategies to support blood-based biomarker testing, timely diagnosis, and access to new treatments.
Dr Sasha Bozeat (Roche) concluded by highlighting early detection and real-world evidence to ensure equitable access and lasting value across healthcare systems.
